Gilead seeks approval for Hepatitis C drug that's innovative — and expensive San Francisco Chronicle (blog) Gilead is also taking heat internationally for its plans to bring Sovaldi to India and other developing countries at a fraction of the U.S. price, about $2,500 for six months of treatment, according to an interview with an Indian pharmaceutical ... |
